PathAI logo

The utility of AI-powered spatial classification of intratumoral CD8+ immune-cell topology in predicting overall survival in patients with melanoma as part of the CheckMate 067 clinical trial

SITC 2021

Study Background

Using an artificial intelligence (AI)-driven algorithm, we retrospectively assessed the value of intratumoral CD8 topology together with PD-L1 expression as a composite biomarker of response to immunotherapy in patients with advanced melanoma in the phase 3 CheckMate 067 clinical trial (NCT01844505)
View Poster


Lee et al.